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In anecdotal case reports, verapamil and nifedipine, cal- 
cium channel blockers, have provided rapid and dramatic 
relief in refractory Tourette syndrome [ 1,2]. The following 
report illustrates the use of nifedipine to augment 
haloperidol in the treatment of a child who did not respond 
when either drug was used alone. 
This 9-year-old boy was referred for intractable Tourette 
syndrome over a 3 year period with associated attention 
deficit hyperactivity disorder. His tics had worsened over 
the previous 5 months, making fine motor control impos- 
sible. He had received a variety of medications, including 
clonidine, haloperidol, pimozide, and fluphenazine, all of 
which proved ineffective. Neurologic examination, includ- 
ingcranial computedtomography,electroencephalography, 
and magnetic resonance imaging, was normal. 
The patient received a therapeutic trial of nifedipine; tics 
and vital signs were monitored. After i week of therapy 
there was neither relief of symptoms, nor presence of side 
effects. Blood pressure and pulse remained stable. With the 
addition of haloperidol (2 mg/day orally in 2 divided doses), 
there was a significant reduction in tics and a marked im- 
provement in attention and school performance. 
Nifedipine was discontinued to determine whether the 
observed improvement was due to haloperidol. Within 2 
days the tics worsened and his attention deficit returned to 
pretreatment levels. To determine whether the deterioration 
in function was due to a placebo effect, a placebo was ad- 
ministered (3 tablets per day at equal intervals): the patient 
and patient's family were told that it was a "medication 
similar to nifedipine." The patient continued to receive the 
placebo for 10 days, during which time his tics and atten- 
tional difficulties continued. After 10 days, nifedipine 
therapy was reinstated. Within 2 weeks the patient's tics 
were markedly improved. His school performance also im- 
proved because of an increase in attention, a decrease in im- 
pulsivity, a decrease in the frequency and severity of tics, 
and an improvement in fine motor control. 
This is the first report to systematically demonstrate the 
use of nifedipine to augment haloperidol treatment of 
Tourette syndrome. These results suggest that an alterna- 
tive in the treatment of Tourette syndrome in treatment- 
resistant cases is the combination of haloperidol and 
nifedipine. In addition to the marked reduction in tics, 
characteristics of attention deficit disorder were affected: 
attention improved and impulsivity decreased. The precise 
basis of the psychopharmacologic impact remains unclear: 
however, neither nifedipine nor haloperidol alone altered 
his course. We postulate that the effect observed in this 
patient represents functional reduction in dopamine recep- 
tors with the chronic administration of nifedipine, with a 
resulting increased efficacy of haloperidol [3]. Further 
studies are indicated to substantiate this effect, and if present, 
to determine its mechanism of action. 
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